Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2019
Parenteral Drugs (India) Limited reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2019. For the quarter, on a standalone basis, the company reported revenue from operations of INR 73.431 million compared to INR 88.949 million a year ago. Loss for the period was INR 283.139 million compared to loss for the year of INR 268.597 million a year ago. Basic and diluted loss per share was INR 9.50 compared to loss per share of INR 9.01 a year ago.
For the half year, on a standalone basis, the company reported revenue from operations of INR 160.591 million compared to INR 194.581 million a year ago. Loss for the year was INR 560.0 million compared to INR 507.00 million a year ago. Basic and diluted loss per share was INR 18.79 compared to loss per share of INR 17.01 a year ago.
For the quarter, on a consolidated basis, the company reported revenue from operations of INR 73.431 million compared to INR 88.949 million a year ago. Loss for the period was INR 283.139 million compared to loss for the year of INR 268.597 million a year ago. Basic and diluted loss per share was INR 9.50 compared to loss per share of INR 9.01 a year ago.
For the half year, on a consolidated basis, the company reported revenue from operations of INR 160.591 million compared to INR 194.581 million a year ago. Loss for the year was INR 560.0 million compared to INR 507.00 million a year ago. Basic and diluted loss per share was INR 18.79 compared to loss per share of INR 17.01 a year ago.